David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.2B |
| 2 |
NVIDIA
NVDA
|
+$1.02B |
| 3 |
T-Mobile US
TMUS
|
+$911M |
| 4 |
Netflix
NFLX
|
+$699M |
| 5 |
Micron Technology
MU
|
+$672M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$768M |
| 2 |
Robinhood
HOOD
|
+$643M |
| 3 |
SCHW
Charles Schwab
SCHW
|
+$534M |
| 4 |
Microsoft
MSFT
|
+$493M |
| 5 |
Intuit
INTU
|
+$472M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.33% |
| 2 | Healthcare | 8.66% |
| 3 | Consumer Discretionary | 8.33% |
| 4 | Financials | 6.44% |
| 5 | Industrials | 6.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSE
3126
DELISTED
Trinseo
TSE
| $987K | ﹤0.01% |
316,474
-69,306
| -18% | -$228K |
|
3127
CALL
Procore
PCOR
$9.21B
| $985K | ﹤0.01% |
14,400
| – | – |
|
3128
Origin Bancorp
OBK
$1.63B
| $985K | ﹤0.01% |
+27,557
| New | +$913K |
|
3129
CALL
Groupon
GRPN
$797M
| $983K | ﹤0.01% |
29,400
-6,700
| -19% | -$171K |
|
3130
Lands' End
LE
$368M
| $978K | ﹤0.01% |
91,280
-21,888
| -19% | -$198K |
|
3131
Kaiser Aluminum
KALU
$2.51B
| $975K | ﹤0.01% |
12,205
-44,013
| -78% | -$3M |
|
3132
BRC Inc
BRCC
$122M
| $972K | ﹤0.01% |
74,213
+28,697
| +63% | +$531K |
|
3133
Amylyx Pharmaceuticals
AMLX
$4.17B
| $971K | ﹤0.01% |
151,502
-118,504
| -44% | -$576K |
|
3134
Arcosa
ACA
$7.13B
| $966K | ﹤0.01% |
11,136
+4,794
| +76% | +$401K |
|
|
FISV
3135
CALL
Fiserv Inc
FISV
$27.9B
| $965K | ﹤0.01% |
+5,600
| New | +$1.02M |
|
3136
OneSpaWorld
OSW
$2.67B
| $962K | ﹤0.01% |
47,184
-101,978
| -68% | -$1.87M |
|
3137
Marqeta
MQ
$1.7B
| $962K | ﹤0.01% |
+41,254
| New | +$783K |
|
3138
WD-40
WDFC
$2.87B
| $962K | ﹤0.01% |
4,216
-7,404
| -64% | -$1.74M |
|
3139
Patterson-UTI
PTEN
$4.39B
| $961K | ﹤0.01% |
161,990
+70,880
| +78% | +$427K |
|
3140
Vanguard Morningstar Mid-Cap ETF
VO
$109B
| $958K | ﹤0.01% |
+13,700
| New | +$899K |
|
3141
Immunovant
IMVT
$8.99B
| $957K | ﹤0.01% |
59,818
+9,284
| +18% | +$140K |
|
3142
Ocular Therapeutix
OCUL
$2.39B
| $954K | ﹤0.01% |
102,833
+42,710
| +71% | +$334K |
|
3143
W.P. Carey
WPC
$16.4B
| $953K | ﹤0.01% |
15,285
+4,820
| +46% | +$297K |
|
3144
Liberty Latin America Class C
LILAK
$1.67B
| $951K | ﹤0.01% |
168,147
-52,170
| -24% | -$256K |
|
3145
SoundHound AI
SOUN
$3.13B
| $951K | ﹤0.01% |
88,586
-6,411,548
| -99% | -$60.4M |
|
3146
Universal Electronics
UEIC
$56.3M
| $949K | ﹤0.01% |
143,406
-21,022
| -13% | -$128K |
|
3147
iShares MSCI Japan Small-Cap ETF
SCJ
$262M
| $948K | ﹤0.01% |
11,169
| – | – |
|
3148
Nabors Industries
NBR
$1.3B
| $946K | ﹤0.01% |
33,774
-6,126
| -15% | -$182K |
|
|
TOPT
3149
iShares Top 20 U.S. Stocks ETF
TOPT
$668M
| $943K | ﹤0.01% |
+34,572
| New | +$860K |
|
3150
Haverty Furniture Companies
HVT
$425M
| $943K | ﹤0.01% |
46,358
-75,026
| -62% | -$1.47M |
|
Similar funds
David Shaw's Q2 2025 Portfolio in Review
As of Q2 2025, David Shaw held 4,838 positions worth $141B, up 26% from $112B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
David Shaw deployed $7.51B of net new capital in Q2 2025, opening 647 new positions and adding to 1,556 existing holdings. Its largest new stake was Sea Limited: 1,365,221 shares worth $218M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was GE Vernova, an estimated $768M trimmed.
- David Shaw's largest Q2 2025 buy was Sea Limited: 1,365,221 shares worth $218M.
- David Shaw added most to Apple in Q2 2025, an estimated $1.2B increase.
- David Shaw's biggest Q2 2025 reduction was GE Vernova, cutting an estimated $768M.
- David Shaw fully exited Novo Nordisk in Q2 2025, selling an estimated $176M.
- David Shaw's ten largest holdings make up 12% of its $141B portfolio in Q2 2025.
- David Shaw opened 647 new positions and closed 532 in Q2 2025.
- David Shaw's portfolio value rose 26% quarter-over-quarter to $141B.
Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.